Selpercatinib in Patients With RET Fusion–Positive Non–Small-Cell Lung Cancer: Updated Safety and Efficacy From the Registrational LIBRETTO-001 Phase I/II Trial

Hypersensitivity Reactions to Selpercatinib Treatment with or Without Prior Immune Checkpoint Inhibitor Therapy in Patients with Non-Small-Cell Lung Cancer in LIBRETTO-001

(2022) Caroline E. McCoach et al.   Journal of Thoracic Oncology

ESMO recommendations on the standard methods to detect RET fusions and mutations in daily practice and clinical research

(2021) C. Belli et al.   ANNALS OF ONCOLOGY

Pemetrexed Plus Platinum With or Without Pembrolizumab in Patients With Previously Untreated Metastatic Nonsquamous NSCLC: Protocol-Specified Final Analysis From KEYNOTE-189

(2021) D. Rodríguez-Abreu et al.   ANNALS OF ONCOLOGY

Therapeutic strategies in RET gene rearranged non-small cell lung cancer

(2021) Leylah M. Drusbosky et al.   Journal of Hematology & Oncology

Intracranial Efficacy of Selpercatinib in RET Fusion-Positive Non–Small Cell Lung Cancers on the LIBRETTO-001 Trial

(2021) Vivek Subbiah et al.   CLINICAL CANCER RESEARCH

Updated overall efficacy and safety of selpercatinib in patients (pts) with RET fusion+ non-small cell lung cancer (NSCLC).

(2021) Benjamin Besse et al.   JOURNAL OF CLINICAL ONCOLOGY

Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study

(2021) Justin F Gainor et al.   LANCET ONCOLOGY

State-of-the-Art Strategies for Targeting RET-Dependent Cancers

(2020) Vivek Subbiah et al.   JOURNAL OF CLINICAL ONCOLOGY

Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non–Small-Cell Lung Cancer

(2020) Shirish Gadgeel et al.   JOURNAL OF CLINICAL ONCOLOGY

Progresses Toward Precision Medicine in RET-altered Solid Tumors

(2020) Carmen Belli et al.   CLINICAL CANCER RESEARCH

Efficacy of Selpercatinib in RET-Altered Thyroid Cancers

(2020) Lori J. Wirth et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung Cancer

(2020) Alexander Drilon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Responsiveness to immune checkpoint inhibitors versus other systemic therapies in RET-aberrant malignancies

(2020) Aparna Hegde et al.   ESMO Open

Phase III study of selpercatinib versus chemotherapy ± pembrolizumab in untreated RET positive non-small-cell lung cancer

(2020) Benjamin J Solomon et al.   Future Oncology

Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry

(2019) J Mazières et al.   ANNALS OF ONCOLOGY

Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial

(2019) Howard West et al.   LANCET ONCOLOGY

Hypersensitivity reactions to therapeutic monoclonal antibodies: Phenotypes and endotypes

(2018) Ghislaine Annie C. Isabwe et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Brief Report: Frequency of Brain Metastases and Multikinase Inhibitor Outcomes in Patients with RET -Rearranged Lung Cancers

(2018) Alexander Drilon et al.   Journal of Thoracic Oncology

Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes

(2017) Alexander Drilon et al.   Nature Reviews Clinical Oncology

RET-rearranged non-small-cell lung carcinoma: a clinicopathological and molecular analysis

(2014) K Tsuta et al.   BRITISH JOURNAL OF CANCER

Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial

(2014) Edward B Garon et al.   LANCET

Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies

(2012) Doron Lipson et al.   NATURE MEDICINE